Longevity, healthspan and aging well

Start here

LongevityLongevity Clinics vs Telehealth: How the Models DifferLongevityLongevity Research: The Published Evidence Base in 2026LongevityBiological age tests: which ones have evidence, which don'tLabshs-CRP: the inflammation marker that predicts more than most testsLabsWho should get a comprehensive biomarker panel and when

All longevity guides (136)

• Alpha-lipoic acid and aging: what research shows

  Alpha-lipoic acid is an antioxidant made in the mitochondria, and levels fall with age. Here is what it is, how it works, and what research shows.

• Autophagy explained: what cellular cleanup is and why it matters

  Autophagy is the body's recycling crew — clearing damaged parts inside cells so the healthy ones can keep working. Why longevity researchers care.

• Autophagy FAQ: the cellular cleanup questions answered

  Autophagy is your cells' recycling program. This FAQ covers what it is, how fasting and exercise trigger it, and what the research supports — in plain terms.

• Biological age tests: which ones have evidence, which don't

  Are biological age tests accurate? A plain-English look at epigenetic clocks, blood-based tests, and telomere kits — which have real evidence and which don't.

• Boron and bone health: what research shows

  Boron is a trace mineral studied for effects on calcium, magnesium, and bone. Here's what the research shows, typical intake, and the upper limit.

• BPC-157 and gut health: what the research shows

  BPC-157 was discovered in gastric juice, and the gastrointestinal literature is its home territory. Here is an honest summary of what the preclinical research shows — and what it does not.

• BPC-157 and TB-500: why these two are often discussed together

  Why BPC-157 and TB-500 are often discussed together in tissue-repair research: the mechanisms, the overlap, and where each stands with FDA.

• BPC-157 and TB-500: why these two peptides are studied together

  BPC-157 and TB-500 are often discussed together in tissue-repair contexts because their proposed mechanisms are complementary. Here is the research rationale — and where each stands with FDA.

• BPC-157 and the brain-gut axis: what the research describes

  BPC-157 and the brain-gut axis in plain English: what the rodent research describes about gut healing, vagal signaling, and why human evidence is still limited.

• BPC-157 for tissue repair and recovery: the evidence

  BPC-157 has been investigated in animal models of tendon, ligament, and muscle injury. Here is what the preclinical research actually shows — and the human evidence gap that remains.

• BPC-157 human trials: what has actually been studied

  BPC-157 has decades of animal data but a much smaller human trial base. Here is exactly what has been studied in humans, what hasn't, and how to read the gap.

• BPC-157: 30 years of animal research, what it tells us

  BPC-157 has 30 years of animal research in plain English: a peptide derived from gastric juice, studied for tissue repair in rodents, with limited human clinical data.

• Calcium alpha-ketoglutarate and the longevity research

  Calcium alpha-ketoglutarate (Ca-AKG) has drawn longevity interest from mouse studies. Here is what the animal and early human data actually show.

• Cardiolipin: the fat that keeps your mitochondria running

  Cardiolipin is a special fat in the inner mitochondrial membrane that keeps energy production efficient. Here is what it does and why it matters with age.

• Cellular senescence and senolytics: what the research shows

  Senescent cells are aging cells that stop dividing but won't die. Here is what cellular senescence is, what senolytics aim to do, and what research shows.

• Centenarian biology: what longevity outliers actually share

  Centenarian biology — what people who live to 100 actually share, where the evidence is solid, and what the lessons mean for the rest of us.

• Copper balance and aging: the trace mineral explained

  Copper is a trace mineral the body needs in tiny amounts and balances against zinc. Here's what copper does, how it's carried, and why balance matters.

• Creatine for women: what the research shows for muscle, bone, and brain

  Creatine isn't just for male lifters. Here's what the published research shows for women's muscle, bone, and brain health, explained in plain English.

• Creatine for women: what the research shows for muscle, bone, and cognition

  A plain-English summary of the creatine research for women — what the data shows on muscle, bone, and cognition, and what older assumptions got wrong.

• Creatine for women: what the research shows for muscle, bone, and cognition

  Creatine is one of the most studied supplements in sports nutrition. For midlife women, the literature on muscle, bone, and brain is now substantial.

• DSIP (delta sleep-inducing peptide): what the research says

  DSIP was isolated in 1977 and has mixed sleep-architecture data in animals and humans. In July 2026, an FDA advisory committee voted against adding it to the 503A bulks list.

• DSIP and sleep quality: what the research actually shows

  DSIP explained: what delta sleep-inducing peptide is, what the research shows on sleep quality, and where the evidence remains thin. Educational only.

• Environmental toxins and hormones: what the research shows

  Endocrine disruptors are everyday chemicals that can interfere with hormones. Here is what the research shows and what is still uncertain, in plain English.

• Epigenetic clocks: can a test measure your biological age?

  Epigenetic clocks read DNA methylation to estimate biological age. Here is how the Horvath clock, GrimAge, and DunedinPACE work and what the research shows.

• Epitalon and sleep: the pineal-gland connection

  Epitalon and sleep: how the pineal-gland peptide may influence melatonin rhythm, what small studies report, and its FDA compounding status after its April 2026 removal from Category 2.

• Epitalon and telomere extension: reading the research carefully

  Epitalon is a four-amino-acid peptide tied to telomere length and pineal-gland research. A careful read of what the studies do and do not show — and where its FDA compounding status stands.

• Epitalon and the telomere research

  Epitalon is a tetrapeptide studied primarily in Russian research for telomerase activation in vitro. US clinical data is sparse. FDA removed it from Category 2 in April 2026, and it is not on the 503A bulks list.

• Ergothioneine: the 'longevity vitamin' from mushrooms

  Ergothioneine is a diet-derived antioxidant from mushrooms that researchers call a possible longevity vitamin. Here is what the science actually shows.

• Estrogen, muscle, and metabolic health: the perimenopause connection

  Estrogen does more than reproduction. It quietly supports muscle, insulin sensitivity, and bone. Here is what happens when it falls in perimenopause.

• Exerkines: the molecules exercise releases, explained

  Exerkines are signaling molecules your body releases during exercise. Here's what klotho, irisin, and MOTS-c do — and what the research actually shows.

• Fasting and autophagy: what the timing research supports

  How long do you need to fast for autophagy? Here is what the timing research supports, what is still unknown, and why the online hour-numbers oversimplify it.

• Fisetin: the plant senolytic researchers study

  Fisetin is a plant flavonoid studied as a senolytic — a compound that clears worn-out cells. Here's what it is, where it's found, and what the data shows.

• Full-body MRI screening: who it helps and who it scares

  Is a full-body MRI worth it? A plain-English look at what these scans detect, the incidental-findings problem, and who benefits versus who just gets scared.

• Glucosamine and longevity: what the mortality data shows

  Beyond joints, glucosamine use has been linked to lower mortality in large studies. Here is what the longevity data shows and what it cannot prove yet.

• GlyNAC: glycine plus NAC and the glutathione question

  GlyNAC pairs glycine with NAC, the two building blocks of glutathione. Here is what a small Baylor trial reported in older adults — and the caveats.

• Grip Strength and Mortality: What the Research Shows

  Grip strength and mortality are linked in large studies: a weaker grip tracks with higher death risk, making it a simple, low-cost health marker.

• Grip strength as a longevity marker: what the research shows

  Grip strength is one of the most replicated longevity predictors in clinical research. Here is what it actually measures and what the studies found.

• Grip strength FAQ: the longevity testing questions answered

  What is normal grip strength by age, how to test it at home, and what it signals about long-term health. Evidence-based answers to common questions.

• Grip strength: why a simple squeeze predicts healthy aging

  Grip strength is one of the simplest predictors of healthy aging. Here is what a hand squeeze reveals about your whole body and how to build it.

• Healthspan vs lifespan: what the longevity field actually studies

  Lifespan is how long you live. Healthspan is how long you live well. Here is what the longevity field is actually studying — and why the distinction matters.

• How autophagy works: the mTOR and AMPK pathways

  How autophagy works in plain English: the mTOR and AMPK switches that tell your cells when to recycle worn-out parts, and what the research shows.

• How much protein you actually need in midlife

  The RDA for protein was set to prevent deficiency — not to protect muscle in midlife. Here's what the research says about how much you actually need.

• How muscle is lost with age: the sarcopenia mechanism

  Sarcopenia is the slow loss of muscle and strength with age. Here is the plain-English mechanism behind it, and why the decline speeds up after age 60.

• How NAD+ fuels cellular energy and DNA repair

  NAD+ is the cellular currency for energy production and DNA repair. How the molecule works, why it declines with age, and what the research shows.

• How Protein Preserves Muscle Through Leucine Signaling

  Leucine, an amino acid in protein, acts as a switch that turns on muscle building. Hitting a leucine threshold each meal helps preserve muscle with age.

• How to improve VO2 max: zone 2 and interval training

  How to improve VO2 max: combine easy zone 2 volume with short, hard intervals like the Norwegian 4x4 in one weekly training plan, not either alone.

• How VO2 max reflects heart and mitochondrial capacity

  VO2 max measures how much oxygen your body uses at peak effort. Learn how your heart and mitochondria determine it — and what training can change.

• How Zone 2 Training Improves Mitochondrial Efficiency

  Zone 2 training works by recruiting mitochondria-rich muscle fibers, but a 2025 review found its edge over harder training is not established.

• IGF-1 LR3: what the research actually shows

  IGF-1 LR3 is a modified analog of IGF-1 with a longer half-life. Animal model data exists, but human safety evidence is limited. Here's an honest read of the literature.

• Inflammation as accelerator: how chronic low-grade inflammation drives aging

  Inflammation and aging in plain English: how chronic low-grade inflammation quietly accelerates age-related decline, and which markers reveal it.

• Klotho, the longevity protein: what the research actually shows

  Klotho is a protein named after the Greek fate who spins life's thread. Here is what it does, why scientists tie it to aging, and what is still unproven.

• Longevity Clinics vs Telehealth: How the Models Differ

  Longevity clinic cost often runs into the thousands a year. Telehealth offers labs, review and prescribing online for less. See what each model includes.

• Longevity Drugs vs. Longevity Peptides: How They're Positioned

  Rapamycin and metformin have the deepest longevity evidence base. Peptides sit earlier on the research curve. Here is how the two categories are positioned.

• Longevity medicine FAQ: the questions people actually ask

  Longevity medicine measures age-related change before it becomes disease. Straight answers on healthspan, evidence, and biological age tests inside.

• Longevity peptides vs supplements: comparing evidence levels

  Peptides and supplements live on a spectrum of evidence — from rodent-only data to large human trials. Here is how to read the levels without falling for hype.

• Longevity Research: The Published Evidence Base in 2026

  Longevity research 2026, sorted by evidence: what has human data, what so far works only in mice (rapamycin: 9% to 25% longer life), and what is still early.

• Longevity science: how to tell evidence from hype

  Longevity science: a plain-English framework for telling real research from hype. Animal vs human data, sample sizes, surrogates, and what claims actually mean.

• Magnesium and healthy aging: what the evidence shows

  Magnesium supports hundreds of body processes. Older adults absorb less and excrete more. Here's what the NIH says about needs, food sources, and forms.

• MOTS-c and exercise: the mitokine that mimics physical activity

  MOTS-c as an exercise mimetic in plain English: a mitochondria-derived peptide that rises with physical activity and signals metabolic flexibility. What the research shows.

• MOTS-c and exercise: why physical activity may be a natural secretagogue

  MOTS-c is a mitochondria-derived peptide that rises with aerobic exercise. Researchers think it may help explain exercise's metabolic and longevity benefits.

• MOTS-c and longevity: why a mitochondrial peptide has researchers paying attention

  MOTS-c longevity research in plain English: a 16-amino-acid peptide encoded inside the mitochondria that may signal metabolic flexibility. What the literature actually shows — and what it does not.

• MOTS-c: the mitochondria-derived peptide explained

  MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. Here is what the peptide is, what the metabolic research describes, and its current access status.

• MOTS-c: the mitochondria-derived peptide in the literature

  MOTS-c is a peptide encoded by mitochondrial DNA, discovered in 2015. Animal data shows metabolic and exercise-capacity effects via AMPK. FDA removed it from Category 2 on April 22, 2026.

• mTOR Explained: The Growth-vs-Repair Switch Rapamycin Targets

  What is mTOR? A plain-English guide to the cellular growth-vs-repair switch rapamycin research targets, and what the longevity evidence actually shows.

• Myostatin: the body's brake on muscle growth, explained

  Myostatin is a protein your body makes to put a brake on muscle growth. Here's what it is, how it works, and what research says about blocking it.

• NAD and aging: what the research actually shows

  NAD is a molecule your cells need for energy, and it declines with age. Here is what the research shows about NAD, NMN, and NR — and what it does not yet prove.

• NAD+ and peptides: how longevity physicians are combining protocols

  Some longevity physicians combine NAD+ precursors with peptides. Here's the rationale, what the research supports, and what remains theoretical.

• NAD+ and peptides: how they work in complementary lanes

  NAD+ supports cellular energy. Peptides act through specific receptors. They are not competitors — they live in different lanes of the longevity conversation.

• NAD+ explained: coenzyme, not peptide

  What is NAD+? A plain-English primer on the coenzyme behind cellular energy, why it declines with age, and why it is not actually a peptide.

• NAD+ IV vs oral precursors: what the delivery research shows

  NAD+ IV delivers it straight to blood; oral NMN and NR raise blood NAD+ 22-142% in trials. Here's what the delivery research actually shows.

• NAD+ Side Effects: What to Know About High-Dose Use

  NAD+ side effects range from flushing, nausea, and cramping with fast IV use to limited long-term safety data on high-dose NR and NMN supplements.

• NAD+ vs NMN vs NR: comparing the three approaches

  NAD+, NMN, and NR all aim to refuel the same cellular battery. Here is the plain-English difference between the three, and what human research actually shows.

• Osteoporosis prevention starts at 35

  Your bones peak in your late 20s and slowly decline after. Here is why osteoporosis prevention really starts decades earlier, in plain English.

• Peptides and Alzheimer's: what the emerging literature describes

  Peptides and Alzheimer's research in plain English: what the early literature describes, where animal data dominates, and why claims should be cautious.

• Peptides for sleep: what the evidence actually supports

  Which peptides actually have human sleep evidence and which do not? A plain-English review of DSIP, sermorelin, CJC-1295/ipamorelin, and epitalon.

• Perimenopause and muscle loss: why the 40s are the critical metabolic window

  Women lose muscle faster in their 40s than at any prior decade. Here is why perimenopause changes the math — and what the research says about pushing back.

• Perimenopause and muscle loss: why the 40s are the critical metabolic window

  Perimenopause accelerates muscle loss for many women. Here is what published research shows about estrogen, lean mass, and the metabolic window of the 40s.

• Protein and longevity research: what the evidence supports in 2026

  Protein and longevity research is split: the RDA covers deficiency, PROT-AGE backs more for aging muscle, and one mortality link reverses after 65.

• Protein intake FAQ: the midlife nutrition questions answered

  How much protein in midlife? PROT-AGE recommends 1.0-1.2 g/kg daily, roughly 70-84 grams for a 70 kg adult, spread across meals from plant or animal sources.

• Rapamycin: the longevity drug researchers watch most

  Rapamycin is an FDA-approved immunosuppressant studied off-label for healthy aging. Here is what mTOR inhibition is and what the research actually shows.

• Resistance training and protein: the sarcopenia floor

  Resistance training plus adequate protein is the evidence-based floor under sarcopenia prevention. The numbers and the mechanism. Educational only.

• Resistance training vs cardio for women's longevity

  For women's longevity, is lifting or cardio better? The honest answer is both, for different reasons. Here is what the research shows, in plain English.

• Sarcopenia explained: the muscle loss most people miss

  Sarcopenia is the gradual age-related loss of muscle mass, strength, and function. Here is what it is — and why catching it early matters in plain English.

• Sarcopenia FAQ: the muscle loss questions people ask

  Sarcopenia FAQ: when it starts, how it's diagnosed, if it's reversible, whether cardio helps, and how it differs from frailty — answered in plain English.

• Sauna and longevity: what the heat research shows

  Sauna use is linked to lower cardiovascular and all-cause mortality in large studies. Here is what the heat-exposure research shows and what it cannot prove.

• Selank and anxiety research: what the Russian studies actually show

  Selank and anxiety: what the Russian clinical literature on this Phase-2 peptide actually reports, the mechanism in plain English, and current access status.

• Selank: a Russian research compound with anxiolytic history

  Selank is a heptapeptide analog of tuftsin with Russian clinical data for anxiety. It is not FDA-evaluated. FDA removed it from Category 2 in September 2024, and it is not on the 503A bulks list.

• Selenium and healthy aging: the antioxidant mineral

  Selenium is a trace mineral your body uses to build antioxidant proteins. Here's what selenium does, how it links to aging, and how much you need.

• Semax: a nootropic peptide under FDA reclassification

  Semax is an ACTH(4-10) heptapeptide analog with Russian clinical use for stroke and cognition. FDA removed it from Category 2 on April 22, 2026.

• Senolytics: Clearing 'Zombie Cells' and the Dasatinib-Quercetin Story

  What are senolytics? A plain-English look at senescent 'zombie cells' and the dasatinib-plus-quercetin research — what trials show and what's still unproven.

• Sleep Peptides vs Melatonin: How the Approaches Differ

  Sleep peptides vs melatonin: how DSIP and melatonin differ in evidence, regulatory status, and what each one is actually studied to do for sleep.

• Sleep quality and aging: what the research actually shows

  Sleep changes measurably with age — less deep sleep, more fragmentation, lighter mornings. Here is what the research shows and how it interacts with the rest of healthy aging.

• Spermidine: the autophagy nutrient in food

  Spermidine is a natural compound in food that researchers study for autophagy and longevity. Here's what it is, where it's found, and what the data shows.

• SS-31 (elamipretide): the mitochondria-targeting peptide in trials

  SS-31, or elamipretide, is a peptide studied for failing mitochondria. Here is what it targets, what the trials show so far, and why it is not approved yet.

• Sulforaphane and Nrf2: the broccoli-sprout antioxidant

  Sulforaphane, made when you chew broccoli sprouts, is studied for turning on Nrf2, the cell's antioxidant switch. See what cell, animal, and human data show.

• Taurine and aging: what the 2023 research actually found

  A 2023 study put taurine on the longevity map. Here is what the research showed in animals, what it did not show in humans, and how to read the headlines.

• TB-500 and tissue repair: separating signal from noise

  TB-500 (thymosin beta-4) has decades of animal data on tissue repair but limited human evidence. Here is what the literature shows — and what it does not.

• TB-500 for tissue repair: what the research shows

  TB-500 has been investigated in animal models of musculoskeletal, cardiac, and dermal injury. Here is what the preclinical research shows — and the human evidence gap that remains.

• Tesamorelin and visceral fat research

  Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Here's what published trials show about its effects on visceral adipose tissue.

• The consequences of sarcopenia: why early action matters

  Sarcopenia — age-related muscle loss — raises your risk of falls, frailty, and early death. Learn why acting early is the smartest move you can make.

• The hallmarks of aging — and which peptides target which

  Researchers describe twelve hallmarks of aging. Here is which ones the most-studied peptides actually engage with — and where the evidence stops.

• The hallmarks of aging: how the field maps biological decline

  The hallmarks of aging in plain English — the 12 biological processes longevity researchers track, and why this framework guides modern preventive medicine.

• The Huberman peptide list: what he's actually said and what the data shows

  Andrew Huberman has discussed several peptides on his podcast. Here is what he has actually said, which compounds he's been cautious about, and what the published research supports.

• The IGF-1 trade-off: GH peptides and long-term risk

  Higher IGF-1 helps muscle and recovery, but population studies link the top of the range to cancer and mortality signals. Here is what the literature shows.

• The longevity-clinic boom: telling substance from theater

  Longevity clinics are booming, and quality varies widely. Here is how to tell evidence-based longevity medicine from expensive theater before you sign up.

• The thymus and aging: why thymosin research matters more at 50

  The thymus shrinks steadily after puberty. By age 50, most of it is replaced by fat. Here is what that means for immune aging — and what the thymosin research explores.

• Thymosin alpha-1 dosing: what published protocols describe

  Published thymosin alpha-1 dosing comes from international Zadaxin trials. Here is what the trial protocols describe — and why dosing is a physician decision.

• Thymosin alpha-1 FAQ: the top questions answered

  Thymosin alpha-1 FAQ — what it is, how it works, who it is for, side effects, and regulatory status. Plain-English answers to the most common Tα1 questions.

• Thymosin alpha-1 research: where it has been studied

  Thymosin alpha-1 has decades of clinical research behind it, mostly in infectious disease and immune contexts. Here is what the thymosin alpha-1 research base actually shows.

• Thymosin alpha-1 side effects and contraindications

  Thymosin alpha-1 side effects in trials are usually mild — injection-site soreness, mild flu-like feeling, occasional rash. Plus the contraindications.

• Thymosin alpha-1: what this immune peptide is

  Thymosin alpha-1 in plain English — what it is, where it comes from in the body, and why physicians are paying attention to this immune-modulating peptide.

• Urolithin A and mitophagy: what the longevity research shows

  Urolithin A is a gut-made compound studied for clearing worn-out mitochondria. Here is what mitophagy means and what early human research actually shows.

• Vitamin B12 and aging: what the research shows

  Vitamin B12 absorption drops with age, so deficiency is common in older adults. Here is what B12 does, why it falls, and what the research shows.

• Vitamin D and healthy aging: what the research actually shows

  Vitamin D shapes bone, muscle, and immune health as we age. Here is what the research actually shows, what the test means, and where the hype runs ahead.

• Vitamin E tocotrienols and healthy aging

  Vitamin E tocotrienols are a less common form of vitamin E studied as antioxidants. Here's how they differ from tocopherols and what aging research shows.

• Vitamin K2 and arterial aging: what research shows

  Vitamin K2 (menaquinone) helps activate proteins that manage calcium. Here's what the research shows about vitamin K2 and arterial aging, told plainly.

• VO2 Max and Longevity: What the Research Shows

  VO2 max and longevity are tightly linked: research ties higher cardiorespiratory fitness to lower mortality, with the least-fit facing several times the risk.

• VO2 max explained: what this longevity metric measures

  VO2 max is the most-studied longevity number you can measure. It estimates how much oxygen your body can use per minute — a strong predictor of lifespan.

• VO2 Max FAQ: The Fitness and Longevity Questions Answered

  VO2 max FAQ: what counts as a good score by age, how often to retest, and what the longevity research actually shows about this fitness metric.

• What Matt Kaeberlein's longevity research tells us about tissue repair

  Matt Kaeberlein's work at UW spans rapamycin, aging clocks, and tissue repair. Here's what his research framework tells us about peptide-assisted recovery.

• What Peter Attia said about gray-market peptides: the full context

  Peter Attia has spoken cautiously about peptides without medical supervision. Here's what he's actually said and why it matters for most patients.

• Who asks about DSIP and the sleep questions behind it

  DSIP (delta sleep-inducing peptide) is an old research peptide tied to sleep. Here's who asks about DSIP, what the science shows, and its regulatory status.

• Who asks about epitalon and the longevity questions behind it

  People ask about epitalon after reading about telomeres and aging. Here is what the research shows, what it does not, and its FDA status in 2026.

• Who Asks About IGF-1 LR3 and the Goals Behind the Question

  Who searches for IGF-1 LR3 and why? A plain-language look at the muscle-signaling research, its regulatory status, and the trade-offs to weigh first.

• Who asks about MOTS-c and what they want to understand

  MOTS-c is a mitochondrial-derived peptide tied to metabolism and exercise in research. Here's who asks about it and what the science actually shows.

• Who Asks About Selank and the Cognitive Questions Behind the Search

  Who searches for Selank and why? A plain-language look at the anxiolytic research, its FDA compounding status, and what to know before considering it.

• Who Asks About Semax and What Draws People to the Topic

  Who searches for Semax and why? A plain-language look at the cognitive research, its FDA compounding status, and what to know before considering it.

• Who is at risk for sarcopenia and the signs to notice

  Sarcopenia affects roughly 1 in 3 adults over 70, but muscle loss starts decades earlier. Here is who is most at risk and what signs to watch for.

• Who is drawn to longevity medicine and why

  Longevity medicine attracts a specific kind of person — not the worried well, but the proactively curious. Here is who seeks it out and why it matters.

• Who should track VO2 max and at what frequency

  Who benefits most from tracking VO2 max, how often to test it, and why this single metric predicts longevity better than almost any other number.

• Why intermittent rapamycin dosing is the research focus

  Rapamycin is FDA-approved for organ transplants. Learn why researchers study intermittent, weekly rapamycin dosing instead of daily use in longevity research.

• Zinc and immune aging: what the research shows

  Zinc helps run the immune system, and older adults are more likely to fall short. Here's what research says about zinc and immune aging, plus honest limits.

• Zone 2 cardio explained: what it is and who it is for

  Zone 2 cardio explained: what heart rate it targets, why it builds metabolic health, and who benefits most from making it a regular training priority.

• Zone 2 training explained: why this pace matters

  Zone 2 is the pace at which your body burns fat efficiently and builds aerobic capacity. Here's what it is, how to find it, and why scientists love it.

• Zone 2 training: how to actually do it

  Zone 2 training works — if you actually stay in it. Here's how to find your zone, pick a modality, and avoid the #1 mistake that makes it useless.

• Zone 2 training: the longevity workout most people skip

  Zone 2 training is easy, conversational cardio that builds your aerobic base. Here is what it is, how it works, and why it matters for healthy aging.